Author: Sandra Henneking

The US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to our CE-certified test TrucheckTM Breast, a blood test for the detection of early-stage breast cancers. Breakthrough Designation is awarded by the US FDA for innovative devices/analyses that have the potential to ensure more effective diagnosis of life-threatening diseases such as cancer. The… Continue reading US FDA grants ‘Breakthrough Designation’ for our blood test used for early detection of breast cancer

Datar Cancer Genetics has so far focused on comprehensive molecular profiling of cancers, especially in advanced solid tumours. Due to the extensive clinical trials in recent years in the field of liquid biopsy with over 40,000 patients, it is now also possible for us to provide a screening solution for solid tumours. Click here for… Continue reading DCG expands Product Portfolio to Screening-Test

We are excited to be partnering with Iylon Precision Oncology. The US-based company works with experts from around the world to create a personalised, evidence-based and optimised treatment recommendation for each patient. In future, they will also use our innovative product services based on molecular and cell analyses for their recommendations. Prof Sendurai Mani, co-founder… Continue reading Our cooperation with Iylon Precision Oncology